Belgian biopharmaceutical company Cardio3 Biosciences, which is backed by a consortium of venture capital firms, has announced that it is considering listing new shares in an IPO.
The company, which raised €19m last month from existing investors in the form of €7m in fresh equity and €12m as a conversion of convertible loans, hopes to raise new funds through an IPO on NYSE...
Backers include Ad4Ventures, the venture capital arm of Italian telecommunications group Mediaset
Backers in the investment round include KfW Bank, IBB Beteiligungsgesellschaft and Hich-Tech Gründerfonds
Digital documentation business will look to expand into new segments and international markets
Capital restructuring enables ICG to exit the French home help services provider